South Miami, Florida 33143

  • Gout


This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects of RDEA3170 administered in combination with allopurinol compared with allopurinol administered alone in adult subjects with gout.


Inclusion Criteria: - Subject is able to understand the study procedures and the risks involved and is willing to provide written informed consent before the first study-related activity. - Subject meets one or more criteria for the diagnosis of gout as per the American Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary Gout. - Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 45 kg/m2. - Subject has a Screening serum urate level ≥ 8 mg/dL. - Subject is free of any clinically significant disease or medical condition, per the Investigator's judgment. Exclusion Criteria: - Subject is unable to take colchicine for gout flare prophylaxis. - Subject has a history or suspicion of kidney stones. - Subject has any gastrointestinal disorder that affects motility and/or absorption. - Subject had unstable angina, New York Heart Association class III or IV heart failure, ischemic heart disease, stroke, or deep venous thrombosis within 12 months prior to Day 1; or subject is currently receiving anticoagulants. - Subject has Screening laboratory parameters that are outside the normal limits and are considered clinically significant by the Investigator. - Subject has an estimated creatinine clearance < 60 mL/min calculated by the Cockcroft-Gault formula using ideal body weight during the Screening period. - Subject is taking losartan, fenofibrate, guaifenesin, or sodium-glucose linked transporter-2 inhibitors; chronic and stable doses are permitted if doses are stable for at least 14 days prior to study medication dosing. - Subject is unable or unwilling to comply with the study requirements or has a situation or condition that, in the opinion of the Investigator, may interfere with participation in the study.



Primary Contact:

Study Director
Jesse Hall, MD
Ardea Biosciences, Inc.

Backup Contact:


Location Contact:

South Miami, Florida 33143
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.